On March 8, 2022 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that the Company will participate at the 34th Annual Roth Conference in Laguna Niguel, California, March 14 and 15 (Press release, GlycoMimetics, MAR 8, 2022, View Source [SID1234609661]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Zegbeh Jallah, Ph.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at View Source, beginning Tuesday, March 15 at approximately 2:00 p.m. PST.

On March 8, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in New Orleans from April 8-13, 2022 (Press release, Kura Oncology, MAR 8, 2022, View Source [SID1234609678]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to showcasing the four abstracts for tipifarnib, including a late-breaking presentation highlighting the opportunity for our next-generation farnesyl transferase inhibitor program," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "We are excited about this emerging opportunity, focused on delaying the onset of drug resistance and look forward to sharing more detailed information at AACR (Free AACR Whitepaper) next month. In the meantime, we intend to perform initial clinical evaluation with tipifarnib in non-small cell lung cancer while in parallel advancing KO-2806, the lead development candidate in our next-generation farnesyl transferase inhibitor program, through IND-enabling studies."

Session titles and information for the four abstracts are listed below and are now available on the AACR (Free AACR Whitepaper) online itinerary planner.

Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry
Session Date and Time: Monday Apr 11, 2022; 1:30 PM – 5:00 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 16
Abstract / Poster: LB080 / 5

A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial)
Session Title: Phase I Trials in Progress 2
Session Date and Time: Wednesday Apr 13, 2022; 9:00 AM – 12:30 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 35
Abstract / Poster: CT253 / 14

Tipifarnib potentiates the antitumor effects of PI3Ka blockade in HNSCC via convergent inhibition of mTOR activity
Session Title: Experimental and Molecular Therapeutics – Mechanisms of Drug Action 3
Session Date and Time: Monday Apr 11, 2022; 9:00 AM – 12:30 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 24
Abstract / Poster: 1120 / 10

Translating genotype to immunophenotype in HRAS mutated head and neck squamous cell carcinoma (HNSCC) to identify effective Tipifarnib partners for optimal patient outcomes
Session Title: Tumor Biology – Models and Technical Approaches to Analyze and Examine the Tumor Microenvironment
Session Date and Time: Wednesday Apr 13, 2022; 9:00 AM – 12:30 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 14
Abstract / Poster: 3882 / 27

Copies of the presentations will be available on Kura’s website at www.kuraoncology.com/pipeline/publications/ following presentation at the meeting.

On March 8, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, reported that its Chief Executive Officer, Zachary Hornby, will present at the Oppenheimer 32nd Annual Healthcare Conference, which will take place virtually (Press release, Boundless Bio, MAR 8, 2022, View Source [SID1234609694]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, March 15, 2022
Time: 2:00 PM – 2:30 PM ET

On March 8, 2022 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand allelic status of STEP2 genes at the upcoming 2022 AACR (Free AACR Whitepaper) Annual Meeting, being held in New Orleans on April 8-13, 2022 (Press release, Repare Therapeutics, MAR 8, 2022, View Source [SID1234609711]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details on RP-3500 Phase 1/2 TRESR Trial Results:
Title: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial
Presenter: Dr. Timothy Yap, MBBS, Ph.D., FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
Abstract Number: CT030
Session Title: Clinical Trials Minisymposium – Patient Selection Strategies for Molecularly Targeted Agents in Clinical Trials
Date/ Time: Monday, Apr 11, 2022 at 2:30 PM – 4:30 PM CT

Poster Presentation Details on SNiPDx Panel for Synthetic Lethal Drug Discovery:
Title: Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin embedded (FFPE) tumor samples using a novel tumor-only sequencing panel with error correction
Presenter: Dominik Glodzik, Ph.D., Repare Therapeutics, Instructor in Biomedical Informatics, Harvard Medical School
Abstract Number: 2801
Session Title: Diagnostic Biomarkers
Date/ Time: Tuesday, April 12, 2022 at 9:00 AM CT

About Repare Therapeutics’ SNIPRx Platform

Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

On March 8, 2022 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, reported that the Company will present the updated data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at AACR (Free AACR Whitepaper) (American Association for Cancer Research) 2022 (Press release, PharmAbcine, MAR 8, 2022, View Source [SID1234609728]). The event will take place both onsite (New Orleans, Louisiana) and online over April 8-13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME
Session category/title: Preclinical/Immunotherapy
Presentation Type: Online (E-poster)
Date: April 8, 2022

PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in the development to treat various tumor types. VISTA is an immune checkpoint receptor that is mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). It is known to play a pivotal role in maintaining the immunosuppressive environment around the tumor cells. Due to this unique mode of action, PMC-309 can provide a promising immunotherapeutic strategy and help address unmet medical needs.

"We are delighted to share the newly updated data of PMC-309 at this important annual event," said Dr. Jin-San Yoo, CEO of PharmAbcine. "Last year at both AACR (Free AACR Whitepaper) 2021 and KSMO (Korean Society of Medical Oncology) 2021, the Company presented PMC-309’s nonclinical data as of early-2021. The presentations highlighted that PMC-309 inhibits VISTA pathways on immunosuppressive cells, such as MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells) which resulted in T cell proliferation in in vitro settings and encouraging anti-tumor effects in in vivo studies. This year’s presentation will include PMC-309’s effect on monocyte activation, which is one of key immune-supportive factors. The Company is preparing an IND submission for a global clinical trial in 2022."

The abstract of the presentation is currently available on the AACR (Free AACR Whitepaper) website, and the e-poster will be accessible during the poster session at 1:00 p.m. ET on April 8 and be available for viewing through July 13.